NeuroOne Reports 163% Revenue Growth Driven by Epilepsy Treatment Technology

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced preliminary unaudited product revenue for the fiscal year ended September 30, 2025, with expectations of reaching a record $9.1 million. This represents a significant 163% increase compared to the $3.5 million reported in fiscal 2024. The company also reported preliminary cash and cash equivalents of $6.6 million as of September 30, 2025.

Chief Executive Officer Dave Rosa attributed the substantial revenue growth to expanded customer interest and positive outcomes with the OneRF Ablation system for patients suffering from seizures associated with epilepsy. Rosa stated that the company believes it is well positioned to expand use of the OneRF technology platform. The complete financial results for the quarter are expected to be announced in December 2025, with the current preliminary results subject to completion of accounting and interim review procedures.

The company will host a virtual investor webinar to discuss its business operations and recent updates. The webinar will feature presentations from CEO Dave Rosa, who will provide an overview of the business model and discuss recent milestone achievements, and Chief Financial Officer Ron McClurg, who will provide a financial overview. The event will include a question-and-answer session following the presentations. Additional information about the company can be found at https://nmtc1.com.

The preliminary financial information released represents management's current estimates and has been prepared in good faith on a consistent basis with prior periods. However, prospective investors should exercise caution in relying on this information as it is subject to adjustment and should not be viewed as a substitute for full financial statements prepared in accordance with United States generally accepted accounting principles. The original release can be viewed on https://www.newmediawire.com.